Champions Oncology, Inc. (FRA:2I3)

Champions Oncology Statistics

Total Valuation

FRA:2I3 has a market cap or net worth of EUR 68.60 million. The enterprise value is 66.02 million.

Market Cap	68.60M
Enterprise Value	66.02M

Important Dates

The next estimated earnings date is Friday, March 13, 2026.

Earnings Date	Mar 13, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	13.89M
Shares Outstanding	n/a
Shares Change (YoY)	+4.06%
Shares Change (QoQ)	+4.85%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	5.19M

Valuation Ratios

The trailing PE ratio is 31.76 and the forward PE ratio is 116.12.

PE Ratio	31.76
Forward PE	116.12
PS Ratio	1.35
PB Ratio	18.70
P/TBV Ratio	20.63
P/FCF Ratio	14.03
P/OCF Ratio	12.71
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.48, with an EV/FCF ratio of 13.50.

EV / Earnings	30.57
EV / Sales	1.33
EV / EBITDA	13.48
EV / EBIT	31.58
EV / FCF	13.50

Financial Position

The company has a current ratio of 0.96, with a Debt / Equity ratio of 1.28.

Current Ratio	0.96
Quick Ratio	0.91
Debt / Equity	1.28
Debt / EBITDA	0.94
Debt / FCF	0.96
Interest Coverage	91.22

Financial Efficiency

Return on equity (ROE) is 98.94% and return on invested capital (ROIC) is 1,811.03%.

Return on Equity (ROE)	98.94%
Return on Assets (ROA)	5.56%
Return on Invested Capital (ROIC)	1,811.03%
Return on Capital Employed (ROCE)	30.71%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	237,810
Profits Per Employee	10,139
Employee Count	213
Asset Turnover	2.11
Inventory Turnover	n/a

Taxes

Income Tax	-63,291
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -50.69% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-50.69%
50-Day Moving Average	5.53
200-Day Moving Average	5.67
Relative Strength Index (RSI)	40.29
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	6.24

Income Statement

In the last 12 months, FRA:2I3 had revenue of EUR 50.65 million and earned 2.16 million in profits. Earnings per share was 0.15.

Revenue	50.65M
Gross Profit	25.38M
Operating Income	2.14M
Pretax Income	2.04M
Net Income	2.16M
EBITDA	3.44M
EBIT	2.14M
Earnings Per Share (EPS)	0.15

Balance Sheet

The company has 7.38 million in cash and 4.69 million in debt, with a net cash position of 2.69 million.

Cash & Cash Equivalents	7.38M
Total Debt	4.69M
Net Cash	2.69M
Net Cash Per Share	n/a
Equity (Book Value)	3.67M
Book Value Per Share	0.26
Working Capital	-701,403

Cash Flow

In the last 12 months, operating cash flow was 5.40 million and capital expenditures -505,461, giving a free cash flow of 4.89 million.

Operating Cash Flow	5.40M
Capital Expenditures	-505,461
Free Cash Flow	4.89M
FCF Per Share	n/a

Margins

Gross margin is 50.11%, with operating and profit margins of 4.22% and 4.26%.

Gross Margin	50.11%
Operating Margin	4.22%
Pretax Margin	4.03%
Profit Margin	4.26%
EBITDA Margin	6.80%
EBIT Margin	4.22%
FCF Margin	9.65%

Dividends & Yields

FRA:2I3 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.06%
Shareholder Yield	-4.06%
Earnings Yield	3.15%
FCF Yield	7.13%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

FRA:2I3 has an Altman Z-Score of 0.83 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.83
Piotroski F-Score	7